NGAL as a biomarker of contrast-induced nephropathy in patients with acute coronary syndrome: controversial and unresolved issues of diagnosis and prevention


DOI: https://dx.doi.org/10.18565/therapy.2019.2.24-29

Mikhaylova Z.D., Shalenkova M.A., Klimkin P.F.

1) City clinical hospital No. 38 of Nizhny Novgorod; 2) City clinical hospital No. 5 of Nizhny Novgorod
Neutrophil gelatinase-associated lipocalin (NGAL) is one of the most promising biomarkers of acute kidney injury (AKI). Objective is to evaluate the possibility of using NGAL as a biomarker of contrast-induced nephropathy (CIN) in patients with acute coronary syndrome (ACS). Material and methods. We examined 113 patients (mean age 59,5 ± 9,6 years) with a diagnosis of ACS. Selective coronary angiography (SSC) was performed in 52,2% of patients. On the 1-3th day of hospitalization, the NGAL content in the blood (s-NGAL) and urine (u-NGAL), serum creatinine (sCr) was determined. Results. AKI (stage 1) was diagnosed in 11 patients with ACS, and only one patient had an AKI verified as CIN. The median s-NGAL (422,04 ng/ml) of u-NGAL (21,8 ng/ml) was higher than the reference values (177 and 72 ng/ml, respectively) in individuals with AKI and CIN in 2,4 and 1,3 times. Conclusions. In the study sample, the frequency of AKI and CIN was 9,7 and 1,7%. The content of NGAL in both blood and urine was not significantly higher in patients with AKI than in patients with ACS without AKI.
Keywords: contrast-induced nephropathy, Кey words: lipocаline, acute coronary syndrome
Read entire article

Literature


  1. Рекомендации ESC/EACTS по реваскуляризации миокарда 2014. Рабочая группа по реваскуляризации миокарда Европейского общества кардиологов (ESC) и Европейской ассоциации кардиоторакальных хирургов (EACTS). Российский кардиологический журнал. 2015; 2(118): 5–81.

  2. Ватутин Н.Т., Зинкович М.И. Контраст-индуцированная нефропатия (обзор литературы и собственные данные). Буковинський медичний вісник. 2015; 19(2): 220–225.

  3. Watabe H., Sato A., Hoshi T., Takeyasu N., Abe D., Akiyama D., Kakefuda Y., Nishina H., Noguchi Y., Aonuma K. Association of contrast-induced acute kidney injury with long-term cardiovascular events in acute coronary syndrome patients with chronic kidney disease undergoing emergent percutaneous coronary intervention. Int. J. Cardiol. 2014; 174(1): 57–63.

  4. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int. (Suppl.) 2012; (2): 1–138.

  5. Научное общество нефрологов России, Ассоциация нефрологов России. Клинические рекомендации по профилактике, диагностике и лечению контраст-индуцированной нефропатии. 2016; 18.

  6. Пролетов Я.Ю., Саганова Е.С., Галкина О.В. Биомаркеры в диагностике острого повреждения почек. Сообщение I. Нефрология. 2014; 18(4): 25–35.

  7. Смирнов А.В., Добронравов В.А., Румянцев А.Ш., Шилов Е.М., Ватазин А.В., Каюков И.Г., Кучер А.Г., Есаян А.М. Национальные рекомендации. Острое повреждение почек: основные принципы диагностики, профилактики и терапии. Часть I. Нефрология. 2016; 20(1): 79–100.

  8. Ronco C., Legrand M., Goldstein S.L., Hur M., Tran N., Howell E.C., Cantaluppi V., Cruz D.N., Damman K., Bagshaw S.M., Di Somma S., Lewington A. Neutrophil Gelatinase-Associated Lipocalin: Ready for Routine Clinical Use? An International Perspective. Blood Purif. 2014; 37(4): 271–85.

  9. Marenzi G., Lauri G., Assanelli E., Campodonico J., De Metrio M., Marana I., Grazi M., Veglia F., Bartorelli A.L. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J. Am. Coll. Cardiol. 2004; 44: 1780–85.

  10. Barrett B.J., Parfrey P.S. Clinical practice. Preventing nephropathy induced by contrast medium. N. Engl. J. Med. 2006; 354(4): 379–86.

  11. You W., Qi C.L., Ye F., Huang S.L., Xie D.J., Wu Z.M., Huang K., Chen K.L., Huang T.Y., Chen S.L. The value of urinary neutrophil gelatinase-associated lipocalin for early diagnosis of contrast-induced nephropathy. Zhonghua Xin Xue Guan Bing Za Zhi. 2016; 24; 44(12): 1024–29.

  12. Torregrosa I., Montoliu C., Urios A., Andrés-Costa M.J., Giménez-Garzó C., Juan I., Puchades M.J., Blasco M.L., Carratalá A., Sanjuán R., Miguel A. Urinary KIM-1, NGAL and L-FABP for the diagnosis of AKI in patients with acute coronary syndrome or heart failure undergoing coronary angiography. Heart Vessels. 2015; 30(6): 703–11.

  13. Ning L., Li Z., Wei D., Chen H., Yang C., Wu D., Wang Y., Zhang J. Urinary semaphorin 3A as an early biomarker to predict contrast-induced acute kidney injury in patients undergoing percutaneous coronary intervention. Braz. J. Med. Biol. Res. 2018; 1; 51(4):e6487.

  14. Wang K., Duan C.Y., Wu J., Liu Y., Bei W.J., Chen J.Y., He P.C., Liu Y.H., Tan N. Predictive value of neutrophil gelatinase-associated lipocalin for contrast-induced acute kidney injury after cardiac catheterization: a meta-analysis. Can. J. Cardiol. 2016; 32(8): 1033.e19–29.

  15. Cecchi E., Avveduto G., D’Alfonso M.G., Terreni A., Gelera E., Caldini A., Giglioli C. Cystatin C, but not urinary or serum NGAL, may be associated with contrastinduced nephropathy after percutaneous coronary invasive procedures: a single center experience on a limited number of patients. Acta Med. Acad. 2017; 46(1): 34–43.

  16. Ribitsch W., Schilcher G., Quehenberger F., Pilz S., Portugaller R.H., Truschnig-Wilders M., Zweiker R., Brodmann M., Stiegler P., Rosenkranz A.R., Pickering J.W., Horina J.H. Neutrophil gelatinase-associated lipocalin (NGAL) fails as an early predictor of contrast induced nephropathy in chronic kidney disease (ANTI-CI-AKI study). Sci. Rep. 2017; 27; 7: 41300.

  17. Урста А.А., Харьков Е.И., Петрова М.М., Урста О.В., Котиков А.Р., Киселев А.Н. Контраст-индуцированная нефропатия у больных с острым коронарным синдромом. Комплексные проблемы сердечно-сосудистых заболеваний. 2016; (3): 106–12.

  18. Erley C.M., Duda S.H., Schlepckow S., Koehler J., Huppert P.E., Strohmaier W.L., Bohle A., Risler T., Osswald H. Adenosine antagonist theophylline prevents the reduction of glomerular filtration rate after contrast media application. Kidney Int. 1994; 45(5): 1425–31.

  19. Matejka J., Varvarovsky I., Vojtisek P., Herman A., Rozsival V., Borkova V., Kvasnicka J. Prevention of contrast-induced acute kidney injury by theophylline in elderly patients with chronic kidney disease. Heart Vessels. 2010; 25(6): 536–42.

  20. Nijssen E.C., Rennenberg R.J., Nelemans P.J., Essers B.A., Janssen M.M., Vermeeren M.A., van Ommen V., Wildberger J.E. Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial. Ned. Tijdschr. Geneeskd. 2018; 161(0): D1734.

  21. Siew E.D., Liu K.D. Contrast-Induced Acute Kidney Injury in the PRESERVE Trial: Lessons Learned. Clin. J. Am. Soc. Nephrol. 2018; 7; 13(6): 949–51.

  22. Leoncini M., Toso A., Maioli M., Tropeano F., Villani S., Bellandi F. Early high - dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: results from the PRATO-ACS study (protective effect of rosuvastatin and antiplatelet therapy on contrast-induced acute kidney injury and myocardial damage in patients with acute coronary syndrome). J. Am.Coll.Cardiol.2014; 63(1): 71–79.


About the Autors

Zinaida D. Mikhaylova, MD, associate professor, consultant of the City clinical hospital No. 38 of Nizhny Novgorod. Address: 603000, Nizhny Novgorod, 22 Chernyshevskogo St. E-mail: zinaida.mihailowa@yandex.ru
Maria A. Shalenkova, MD, associate professor, consultant of the City clinical hospital No. 38 of Nizhny Novgorod. Address: 603000, Nizhny Novgorod, 22 Chernyshevskogo St. E-mail: mshalenkova@yandex.ru
Pavel F. Klimkin, PhD, consultant of the City clinical hospital No. 5 of Nizhny Novgorod. Address: 603000, Nizhny Novgorod, 34 Nesterova St. E-mail: climckin2009@yandex.ru


Similar Articles

Back to Content

Бионика Медиа